泽德曼医药与济川药业达成泽立美乳膏中国独家商业化合作

Group 1 - Shanghai Zedman Pharmaceutical Technology Co., Ltd. has signed an agreement with Jichuan Pharmaceutical Co., Ltd. for exclusive commercialization rights of Zeli Mei in China (excluding Hong Kong, Macau, and Taiwan), with a maximum upfront payment of 190 million yuan and milestone payments [1] - The collaboration is a significant milestone for Zedman in market expansion and resource complementarity, aiming to invigorate pediatric and dermatological drug offerings [1] - Zeli Mei is the first approved AhR modulator for treating eczema in children over 2 years old and adults, addressing clinical pain points of traditional treatments [2] Group 2 - Zedman Pharmaceutical's CEO emphasizes the importance of this collaboration for maximizing the innovative value of Zeli Mei and accelerating its internationalization [2] - Jichuan Pharmaceutical's General Manager highlights the strategic partnership as a key enhancement in pediatric and dermatological treatment product layout, filling a clinical gap for young eczema patients [3] - The partnership aims to leverage Jichuan's established sales network and academic promotion team to expedite the market introduction and clinical adoption of Zeli Mei [3]